je.st
news
For J&J Prostate Cancer Is PARP For The Course
2016-04-07 23:45:50| Food - Topix.net
Johnson & Johnson addressed two issues with one relatively small $35m payment: its position in prostate cancer and absence from PARP inhibition. The big pharma group locked up one of just two unpartnered assets in this rejuvenated class and has chosen to focus its work in prostate cancer, where Zytiga might soon run out of market exclusivity.
Tags: the
cancer
prostate
prostate cancer
Category:Food and Related Products
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||